Author

Gary Chan 1

1 Pfiz

An update on the analysis of non-melanoma skin cancer in the tofacitinib ulcerative colitis programme

Bruce E. Sands, Millie Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

Impact of baseline corticosteroid therapy on tofacitinib induction efficacy and infection risk in patients with ulcerative colitis: data from global clinical trials

Gary Lichtenstein, Benjamin L. Cohen, Leonardo Salese, Arif Soonasra, Irene Modesto, Wenjin Wang, Deborah.A Woodworth, Gary Chan, Daniel Quirk, Chinyu Su, Laurent Peyrin‐Biroulet

INTEGRATED SAFETY ANALYSES OF TOFACITINIB IN ULCERATIVE COLITIS CLINICAL TRIALS

William Sandborn, Julian Panés, Geert R. D'Haens, Bruce E. Sands, Chinyu Su, Michele Moscariello, Thomas V Jones, Ron Pedersen, Gary S. Friedman, Nervin Lawendy, Gary Chan

Tofacitinib for the treatment of ulcerative colitis: an update on the analysis of malignancy rates from the UC clinical programme

Gary R. Lichtenstein, Matthew A. Ciorba, Gerhard Rogler, Daniel Quirk, Andrew J. Thorpe, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Julian Panés

Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates in the tofacitinib ulcerative colitis clinical programme

Kevin L. Winthrop, Edward V. Loftus Jr., Daniel C. Baumgart, Leonardo Salese, Andrew J. Thorpe, Nervin Lawendy, Gary Chan, Ronald D. Pedersen, Walter Reinisch

TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 4.9 YEARS OF TREATMENT

Gary R. Lichtenstein, Edward V. Loftus Jr., Stuart Bloom, Nervin Lawendy, Gary Chan, Gary S. Friedman, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: an interim analysis of an open-label, long-term extension study with up to 5.5 years of treatment

Gary R. Lichtenstein, Edward V. Loftus Jr., Arif Soonasra, Nervin Lawendy, Gary Chan, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Stuart Bloom

Item 1 - 8 / 8
1